ASsessment of Adherence TO Medication in AtRIAl Fibrillation - an eMonitoring Drug Dispensing Device Study (ASTORIA)

University of Oslo (UIO)

Status

Unknown

Conditions

Atrial Fibrillation

Adherence, Patient

Treatments

Behavioral: Adherence

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04815161

171965

Details and patient eligibility

About

The ASTORIA study is a prospective cohort single-armed multicenter observational study that aims to assess adherence to rivaroxaban using a high technological electronical pillbox connected to a phone application in a group of atrial fibrillation patients with indication of long term anticoagulation treatment in routine clinical practice.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female or male patient with age > 18 years
Patients with atrial fibrillation
Patients initiated, continued on or switched to rivaroxaban for the indication atrial fibrillation with intended lifelong treatment (CHA2 DS2-VASc score ≥ 1).
The patient must agree to the use of the electronic medication adherence monitoring device, the so-called Pilloxa box and need to have a sufficient understanding of the app and functionality in conjunction with the use of the Pilloxa box.
Signed informed consent
No participation in an investigational program with interventions outside of routine clinical practice
No contra-indications according to the local marketing authorization

Exclusion criteria

Participation in an investigational program with interventions outside of routine clinical practice
Contra-indications according to the local marketing authorization